Mark Capone Christopher's most recent trade in Mesa Laboratories, Inc. was a trade of 1,301 Common Stock done at an average price of $76.3 . Disclosure was reported to the exchange on March 10, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Mesa Laboratories Inc | Mark Christopher Capone | Director | Purchase of securities on an exchange or from another person at price $ 76.35 per share. | 10 Mar 2026 | 1,301 | 3,429 (0%) | 0% | 76.3 | 99,331 | Common Stock |
| Mesa Laboratories Inc | Mark Christopher Capone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2025 | 2,784 | 2,784 | - | - | Restricted Stock Units - 3 | |
| Mesa Laboratories Inc | Mark Christopher Capone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2025 | 1,404 | 2,128 (0%) | 0% | 0 | Common Stock | |
| Mesa Laboratories Inc | Mark Christopher Capone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2025 | 1,404 | 0 | - | - | Restricted Stock Units - 2 | |
| Mesa Laboratories Inc | Mark Christopher Capone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 1,404 | 1,404 | - | - | Restricted Stock Units - 2 | |
| Mesa Laboratories Inc | Mark Christopher Capone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2024 | 724 | 724 (0%) | 0% | 0 | Common Stock | |
| Mesa Laboratories Inc | Mark Christopher Capone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2024 | 724 | 0 | - | - | Restricted Stock Units - 1 | |
| Mesa Laboratories Inc | Mark Capone Christopher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 724 | 724 | - | - | Restricted Stock Units -1 | |
| DermTech Inc | Mark Christopher Capone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 35,714 | 82,054 (0%) | 0% | 0 | Common Stock | |
| DermTech Inc | Mark Christopher Capone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2022 | 26,480 | 26,480 (0%) | 0% | 0 | Common Stock | |
| DermTech Inc | Mark Christopher Capone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2022 | 19,860 | 46,340 (0%) | 0% | 0 | Common Stock |